Glenmark Pharmaceuticals Inc., USA, has launched Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) in a multiple-dose vial. The product is bioequivalent and therapeutically equivalent to BPI Labs, LLC’s reference listed drug under NDA 205029. The launch is eligible for 180 days of Competitive Generic Therapy (CGT) exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.